keyword
MENU ▼
Read by QxMD icon Read
search

Liver chemoembolization

keyword
https://www.readbyqxmd.com/read/27911488/hepatocellular-carcinoma-as-an-emerging-morbidity-in-the-thalassemia-syndromes-a-comprehensive-review
#1
REVIEW
Hassan M Moukhadder, Racha Halawi, Maria Domenica Cappellini, Ali T Taher
The incidence of hepatocellular carcinoma (HCC) in patients with thalassemia is on the rise. The 2 well recognized HCC risk factors in thalassemia are iron overload and chronic viral infection with hepatitis C. The carcinogenicity of iron is related to its induction of oxidative damage, which results in genotoxicity, and to immunologic dysregulation, which attenuates cancer immune surveillance. Chronic hepatitis B and C infections lead to necroinflammation, which can prompt progression to HCC, but an independent role of hepatitis B virus in hepatic carcinogenesis among patients with thalassemia has not been demonstrated...
December 1, 2016: Cancer
https://www.readbyqxmd.com/read/27905197/adult-hepatoblastoma-a-review-of-47-cases
#2
Xiao-Feng Duan, Qiang Zhao
BACKGROUND: Adult hepatoblastoma is a very rare and aggressive neoplasm. The aim of this study was to review the cases of adult hepatoblastoma patients. METHODS: A search of all case reports about adult hepatoblastoma from 1958 to 2016 by medical database was performed. Data about demographic information, clinical symptoms and signs, laboratory test and imaging examination, treatment and clinical outcomes were extracted and analysed. RESULTS: A total of 43 English articles including 47 cases of adult hepatoblastoma patients were collected...
November 30, 2016: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/27905019/multi-disciplinary-concurrent-management-of-recurrent-hepatocellular-therapy-is-superior-to-sequential-therapy
#3
Tyler D Fields, Prejesh Philips, Charles R Scoggins, Cliff Tatum, Lawrence Kelly, Kelly M McMasters, Robert C G Martin
BACKGROUND: Recurrent hepatocellular carcinoma after a patient's initial therapy, whether it is transplantation, resection, or ablation, remains a challenging clinical problem. Since recurrence occurs in 70% of all initially treated disease within 5 years, optimal management to treat this recurrence is needed. Currently, a bias exists toward mono-therapy (i.e., ablation alone, hepatic arterial therapy alone, or sorafenib therapy alone) instead of concurrent sequential therapy-as is common in other primary and metastatic disease to the liver...
November 30, 2016: World Journal of Surgery
https://www.readbyqxmd.com/read/27904861/a-recent-advance-in-image-guided-locoregional-therapy-for-hepatocellular-carcinoma
#4
REVIEW
Yaoping Shi, Bo Zhai
BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer-related deaths. Hepatic resection and liver transplantation are considered to be the preferred treatment for HCC. However, as novel therapeutic options such as image-guided locoregional therapies have emerged and been refined, the manner in which HCC is treated has changed dramatically compared with what it was considered just 2 decades earlier. SUMMARY: This study reviews the current results of various image-guided locoregional therapies for treating HCC, especially focusing on thermal ablative and transarterial techniques...
October 2016: Gastrointestinal Tumors
https://www.readbyqxmd.com/read/27904450/survival-of-patients-with-intermediate-stage-hepatocellular-carcinoma-treated-with-superselective-transarterial-chemoembolization-using-doxorubicin-loaded-dc-bead-under-cone-beam-computed-tomography-control
#5
Peter Popovic, Borut Stabuc, Rado Jansa, Manca Garbajs
BACKGROUND: The purpose of this retrospective study was to evaluate treatment response, adverse events and survival rates of patients with intermediate stage HCC treated with superselective doxorubicin-loaded DC Bead transarterial chemoembolization (DEBDOX) under cone beam computed tomography (CBCT) control. PATIENTS AND METHODS: Between October 2010 and June 2012, 35 consecutive patients with intermediate stage HCC (32 male, 3 female; average age, 67.5 ± 7.8 years; 22 patients Child-Pugh class A, 8 class B, 5 without cirrhosis) were treated with DEBDOX TACE...
December 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27904254/liver-infarction-after-drug-eluting-embolic-transarterial-chemoembolization-for-hepatocellular-carcinoma-in-the-setting-of-a-large-portosystemic-shunt
#6
REVIEW
Benjamin V Park, Ron C Gaba, R Peter Lokken
No abstract text is available yet for this article.
December 2016: Seminars in Interventional Radiology
https://www.readbyqxmd.com/read/27894729/effect-of-diagnostic-cone-beam-computed-tomography-protocols-on-image-quality-patient-dose-and-lesion-detection
#7
Jijo Paul, Annamma Chacko, Paola Saccomandi, Thomas J Vogl, Nour-Eldin A Nour-Eldin
OBJECTIVE: To evaluate the effect of cone-beam computed tomography (CBCT) image acquisition protocols on image quality, lesion detection, delineation, and patient dose. METHODS: 100-patients and a CTDI phantom combined with an electron density phantom were examined using four different CBCT-image acquisition protocols during image-guided transarterial chemoembolization (TACE). Protocol-1 (time: 6s, tube rotation: 360°), protocol-2 (5s, 300°), protocol-3 (4s, 240°) and protocol-4 (3s, 180°) were used...
November 25, 2016: Physica Medica: PM
https://www.readbyqxmd.com/read/27893681/combination-of-transcatheter-arterial-chemoembolization-and-ct-guided-percutaneous-segment-ablation-for-hepatocellular-carcinoma-therapy-a-retrospective-study
#8
Wei Li, Yang Wang, Wenfeng Gao, Jiasheng Zheng
Treatment option for liver cancer patients with large tumor >5 cm and/or portal vein tumor thrombosis is very limited. New treatment strategy is badly needed. Our study is to determine the safety and treatment efficacy of a new minimally invasive treatment strategy-liver segment thermal ablation.Late-stage hepatocellular carcinoma patients were included and treated with percutaneous ablation to destroy the entire tumor-containing liver segment to reduce reoccurrence and prolong survival. Transcatheter arterial chemoembolization was used before ablation to label tumor margin...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27882236/improved-survival-with-double-platinum-therapy-transcatheter-arterial-infusion-using-cisplatin-and-transcatheter-arterial-chemoembolization-using-miriplatin-for-bclc-b-hepatocellular-carcinoma
#9
Toru Ishikawa, Satoshi Abe, Takayuki Watanabe, Yujiro Nozawa, Tomoe Sano, Akito Iwanaga, Keiichi Seki, Terasu Honma, Toshiaki Yoshida
Transcatheter arterial chemoembolization (TACE) is the standard therapy for Barcelona Clinic Liver Cancer (BCLC) classification intermediate stage B hepatocellular carcinoma (HCC). However, other transcatheter methods, such as transcatheter arterial infusion (TAI), also play an important role in the treatment of advanced HCC. Although it has been reported that TAI with a high concentration of a fine-powder formulation of cisplatin (DDP-H) reduced intrahepatic recurrence and improved survival, the combined use of TAI with DDP-H and TACE has not yet been investigated...
November 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27880724/hepatic-resection-after-transarterial-chemoembolization-increases-overall-survival-in-large-multifocal-hepatocellular-carcinoma-a-retrospective-cohort-study
#10
Junwei Chen, Lisha Lai, Qu Lin, Wensou Huang, Mingyue Cai, Kangshun Zhu, Mingsheng Huang
To investigate the prognosis of transarterial chemoembolization (TACE) followed by hepatic resection (HR) in large/multifocal hepatocellular carcinoma (HCC), the medical records of consecutive HCC patients who underwent TACE between January 2006 and December 2010 were retrospectively analyzed. Patients who received TACE alone comprised the T group (61 patients), while those who received HR after TACE comprised the T+R group (49 patients). All the resections were successfully performed, and only one class V complication occurred...
November 17, 2016: Oncotarget
https://www.readbyqxmd.com/read/27872985/pharmacokinetics-and-histopathological-findings-of-chemoembolization-using-cisplatin-powder-mixed-with-degradable-starch-microspheres-in-a-rabbit-liver-tumor-model
#11
Takeshi Sato, Toshihiro Tanaka, Hideyuki Nishiofuku, Yasushi Fukuoka, Hiroshi Sakaguchi, Tetsuya Masada, Shota Tatsumoto, Nagaaki Marugami, Masato Takano, Ichiro Yamato, Masayuki Sho, Chiho Ohbayashi, Toshiko Hirai, Kimihiko Kichikawa
PURPOSE: The purpose of this study is to evaluate the pharmacokinetics and histopathological findings of transarterial chemoembolization (TACE) using cisplatin powder mixed with degradable starch microspheres (DSM) (Cis/DSM-TACE) compared with cisplatin arterial infusion (Cis-AI). MATERIALS AND METHODS: Eighteen rabbits with VX2 liver tumors were divided into two groups: Cis/DSM-TACE (n = 9) and Cis-AI (n = 9) groups. In the Cis/DSM-TACE group, a mixture of cisplatin powder and DSM was injected until stasis of hepatic arterial flow was achieved...
November 21, 2016: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/27870679/new-developments-in-interventional-oncology-liver-metastases-from-colorectal-cancer
#12
Joseph R Kallini, Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Ahsun Riaz, Robert J Lewandowski, Riad Salem
Colorectal cancer is the third leading cause of cancer death in the United States. Although hepatic excision is the first-line treatment for colorectal liver metastasis (CRLM), few patients are candidates. Locoregional therapy (LRT) encompasses minimally invasive techniques practiced by interventional radiology. These include ablative treatments (radiofrequency ablation, microwave ablation, and cryosurgical ablation) and transcatheter intra-arterial therapy (hepatic arterial infusion chemotherapy, transarterial "bland" embolization, transarterial chemoembolization, and radioembolization with yttrium 90)...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27867681/local-ablative-treatments-for-hepatocellular-carcinoma-an-updated-review
#13
REVIEW
Antonio Facciorusso, Gaetano Serviddio, Nicola Muscatiello
Ablative treatments currently represent the first-line option for the treatment of early stage unresectable hepatocellular carcinoma (HCC). Furthermore, they are effective as bridging/downstaging therapies before orthotopic liver transplantation. Contraindications based on size, number, and location of nodules are quite variable in literature and strictly dependent on local expertise. Among ablative therapies, radiofrequency ablation (RFA) has gained a pivotal role due to its efficacy, with a reported 5-year survival rate of 40%-70%, and safety...
November 6, 2016: World Journal of Gastrointestinal Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27856136/korean-multicenter-registry-of-transcatheter-arterial-chemoembolization-with-drug-eluting-embolic-agents-for-nodular-hepatocellular-carcinomas-six-month-outcome-analysis
#14
Myungsu Lee, Jin Wook Chung, Kwang-Hun Lee, Jong Yun Won, Ho Jong Chun, Han Chu Lee, Jin Hyoung Kim, In Joon Lee, Saebeom Hur, Hyo-Cheol Kim, Yoon Jun Kim, Gyoung Min Kim, Seung-Moon Joo, Jung Suk Oh
PURPOSE: To assess the efficacy and safety of transcatheter arterial chemoembolization with drug-eluting embolic (DEE) agents for nodular hepatocellular carcinoma (HCC). MATERIALS AND METHODS: The study design was a prospective multicenter registry-based, single-arm clinical trial that included 152 patients. One hundred three (67.8%) had a Child-Pugh class/score of A5, 114 (75.0%) had a performance status of 0, and 77 (50.7%) had Barcelona Clinic Liver Cancer (BCLC) stage A disease...
November 14, 2016: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/27846227/survival-analysis-of-single-large-5-cm-hepatocellular-carcinoma-patients-bclc-a-versus-b
#15
Yuri Cho, Dong Hyun Sinn, Su Jong Yu, Geum Youn Gwak, Ji Hoon Kim, Yang Jae Yoo, Dae Won Jun, Tae Yeob Kim, Hyo Young Lee, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon
BACKGROUND & AIMS: Single large (>5 cm) hepatocellular carcinoma (HCC) is classified as Barcelona Liver Clinic (BCLC) stage early stage (A). Yet, controversies exist whether single large HCC can be considered as early stage. We have analyzed long-term outcome to see which stage is appropriate for these patients. METHODS: From 2005 to 2006, 1,546 consecutive patients who were newly diagnosed as HCC (BCLC A or B) at four tertiary hospitals in Korea were analyzed...
2016: PloS One
https://www.readbyqxmd.com/read/27831830/imaging-biomarkers-of-tumor-response-in-neuroendocrine-liver-metastases-treated-with-transarterial-chemoembolization-can-enhancing-tumor-burden-of-the-whole-liver-help-predict-patient-survival
#16
Sonia Sahu, Ruediger Schernthaner, Roberto Ardon, Julius Chapiro, Yan Zhao, Jae Ho Sohn, Florian Fleckenstein, MingDe Lin, Jean-François Geschwind, Rafael Duran
Purpose To investigate whether whole-liver enhancing tumor burden [ETB] can serve as an imaging biomarker and help predict survival better than World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), and European Association for the Study of the Liver (EASL) methods in patients with multifocal, bilobar neuroendocrine liver metastases (NELM) after the first transarterial chemoembolization (TACE) procedure. Materials and Methods This HIPAA-compliant, institutional review board-approved retrospective study included 51 patients (mean age, 57...
November 10, 2016: Radiology
https://www.readbyqxmd.com/read/27826556/living-donor-liver-transplantation-for-hepatocellular-carcinoma-achieves-better-outcomes
#17
REVIEW
Chih-Che Lin, Chao-Long Chen
Liver transplantation (LT) for hepatocellular carcinoma (HCC) at Kaohsiung Chang Gung Memorial Hospital mainly relies on live donor LT (LDLT). Owing to taking the risk of LD, we are obligated to adopt strict selection criteria for HCC patients and optimize the pre-transplant conditions to ensure a high disease-free survival similar to those without HCC, even better than deceased donor LT (DDLT). Better outcomes are attributed to excellent surgical results and optimal patient selection. The hospital mortality of primary and salvage LDLT are lower than 2% in our center...
October 2016: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/27801695/early-response-of-hepatocellular-carcinoma-to-chemoembolization-volume-computed-tomography-liver-perfusion-imaging-as-a-short-term-response-predictor
#18
Tian-Hao Su, Wen He, Long Jin, Guang Chen, Guo-Wen Xiao
OBJECTIVE: The aim of this study was to investigate the efficacy of lesion-oriented whole-liver computed tomography (CT) perfusion for predicting transarterial chemoembolization early treatment response in patients with hepatocellular carcinoma (HCC). METHODS: Volume helical shuttle CT perfusion imaging on the whole liver was prospectively performed on 39 patients with 46 independent HCC lesions before target-selected chemoembolization. The therapeutic effects were assessed: responder group included lesions with a complete and partial response, whereas the nonresponder group contained stable and progressive disease...
October 31, 2016: Journal of Computer Assisted Tomography
https://www.readbyqxmd.com/read/27785449/hepatocellular-carcinoma-a-review
#19
REVIEW
Julius Balogh, David Victor, Emad H Asham, Sherilyn Gordon Burroughs, Maha Boktour, Ashish Saharia, Xian Li, R Mark Ghobrial, Howard P Monsour
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a leading cause of cancer-related death worldwide. In the United States, HCC is the ninth leading cause of cancer deaths. Despite advances in prevention techniques, screening, and new technologies in both diagnosis and treatment, incidence and mortality continue to rise. Cirrhosis remains the most important risk factor for the development of HCC regardless of etiology. Hepatitis B and C are independent risk factors for the development of cirrhosis...
2016: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/27784439/-development-of-callispheres%C3%A2-embolic-microspheres
#20
Y S Guan, Q He, Y Jin, F Yao
CalliSpheres® embolic microspheres for embolization of the vasculature of liver cancer are designed, manufactured, and verified, in order to improve the effect of transcatheter arterial chemoembolization in the treatment of primary liver cancer.
July 20, 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
keyword
keyword
72036
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"